Breast cancer and flavonoids - A role in prevention

Current Pharmaceutical Design

Volumn 19, Issue 34, 2013, Pages 6125-6132

  Takemura, Hitomi ^a,b   Sakakibara, Hiroyuki ^c   Yamazaki, Shunsuke ^b   Shimoi, Kayoko ^b  

^a AICHI GAKUSEN UNIVERSITY   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Breast cancer; Chemoprevention; CYP1B1; Estrogen; Flavonoids

Indexed keywords

ACACETIN; APIGENIN; BAICALEIN; CHRYSIN; CYCLIN D1; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; DAIDZEIN; DIOSMETIN; EPICATECHIN; ERIODICTYOL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FLAVONOID; GALANGIN; GENISTEIN; HESPERETIN; ISORHAMNETIN; KAEMPFEROL; LUTEOLIN; NARINGENIN; PINOCEMBRINE; QUERCETIN; REACTIVE OXYGEN METABOLITE;

BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DETOXIFICATION; DIETARY INTAKE; DNA ADDUCT; DNA METHYLATION; DNA REPAIR; ENZYME ACTIVITY; ESTROGEN METABOLISM; ESTROGEN RESPONSIVE ELEMENT; HORMONAL REGULATION; HUMAN; HYDROXYLATION; KINETICS; LOW CALORY DIET; METABOLIC ACTIVATION; METABOLITE; METASTASIS; MOLECULAR DOCKING; NONHUMAN; PHYSICAL ACTIVITY; POINT MUTATION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TUMOR INVASION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ANTICARCINOGENIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGENS; FEMALE; FLAVONOIDS; HUMANS; MOLECULAR DOCKING SIMULATION;

EID: 84887867907     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319340006     Document Type: Review

References (92)

1. World Health Organization, GLOBOCAN 2008.
2. Lalloo F, Varley J, Ellis D, et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 2003; 361: 1101-2.
3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J Clin 1999; 49: 8-31, 1.
4. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993; 15: 48-65.
5. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993; 15: 36-47.
6. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17-35.
7. IARC WGotEoCRtH. Painting, firefighting, and shiftwork. International Agency for Research on Cancer: Lyon 2010.
8. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67-72.
9. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988; 48: 246-53.
10. Lippman ME, Huff KK, Jakesz R, et al. Estrogens regulate production of specific growth factors in hormone-dependent human breast cancer. Ann N Y Acad Sci 1986; 464: 11-6.
11. Topper YJ, Sankaran L, Chomczynski P, Prosser C, Qasba P. Three stages of responsiveness to hormones in the mammary cell. Ann N Y Acad Sci 1986; 464: 1-10.
12. Weng CJ, Yen GC. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo antimetastatic activities. Cancer Metastasis Rev 2012; 1-2: 323-51.
13. Hollman PC, Katan MB. Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother 1997; 51: 305-10.
14. Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr 2012; 31: 206-38.
15. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In vitro 2006; 20: 187-210.
16. Basa GF, Hirayama T, Cruz-Basa AG. Cancer epidemiology in the Philippines. Natl Cancer Inst Monogr 1977; 47: 45-56.
17. Dunn JE. Cancer epidemiology in populations of the United States-with emphasis on Hawaii and California--and Japan. Cancer Res 1975; 35: 3240-5.
18. Gray GE, Pike MC, Henderson BE. Breast-cancer incidence and mortality rates in different countries in relation to known risk factors and dietary practices. Br J Cancer 1979; 39: 1-7.
19. Miller AB. Present status of breast cancer screening. Can Med Assoc J 1977; 117: 845-6.
20. Bouker KB, Hilakivi-Clarke L. Genistein: does it prevent or promote breast cancer? Environ Health Perspect 2000; 108: 701-8.
21. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113-31.
22. Ganry O. Phytoestrogen and breast cancer prevention. Eur J Cancer Prev 2002; 11: 519-22.
23. Helferich WG, Andrade JE, Hoagland MS. Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 2008; 16: 219-26.
24. Wang Q, Li H, Tao P, et al. Soy isoflavones, CYP1A1, CYP1B1, and COMT polymorphisms, and breast cancer: a case-control study in southwestern China. DNA Cell Biol 2011; 30: 585-95.
25. Cho YA, Kim J, Park KS, et al. Effect of dietary soy intake on breast cancer risk according to menopause and hormone receptor status. Eur J Clin Nutr 2010; 64: 924-32.
26. Iwasaki M, Hamada GS, Nishimoto IN, et al. Isoflavone, polymorphisms in estrogen receptor genes and breast cancer risk in casecontrol studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. Cancer Sci 2009; 100: 927-33.
27. Lampe JW, Nishino Y, Ray RM, et al. Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2007; 16: 2579-86.
28. Iwasaki M, Inoue M, Otani T, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol 2008; 26: 1677-83.
29. Guha N, Kwan ML, Quesenberry CP, Jr., Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat 2009; 118: 395-405.
30. Luo J, Gao YT, Chow WH, et al. Urinary polyphenols and breast cancer risk: results from the Shanghai Women's Health Study. Breast Cancer Res Treat 2010; 120: 693-702.
31. Fink BN, Steck SE, Wolff MS, et al. Dietary flavonoid intake and breast cancer survival among women on Long Island. Cancer Epidemiol Biomarkers Prev 2007; 16: 2285-92.
32. Fink BN, Steck SE, Wolff MS, et al. Dietary flavonoid intake and breast cancer risk among women on Long Island. Am J Epidemiol 2007; 165: 514-23.
33. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 190-7.
34. Mokbel K. Risk-reducing strategies for breast cancer--a review of recent literature. Int J Fertil Womens Med 2003; 48: 274-7.
35. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451-86.
36. Liehr JG. Dual role of oestrogens as hormones and procarcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997; 6: 3-10.
37. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000; 21: 40-54.
38. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593-603.
39. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863-70.
40. Denger S, Reid G, Brand H, Kos M, Gannon F. Tissue-specific expression of human ERalpha and ERbeta in the male. Mol Cell Endocrinol 2001; 178: 155-60.
41. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-alpha and-beta mRNA in the rat central nervous system. J Comp Neurol 1997; 388: 507-25.
42. Hartman J, Strom A, Gustafsson JA. Estrogen receptor beta in breast cancer--diagnostic and therapeutic implications. Steroids 2009; 74: 635-41.
43. Muthyala RS, Ju YH, Sheng S, et al. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R-and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem 2004; 12: 1559-67.
44. Choi SY, Ha TY, Ahn JY, et al. Estrogenic activities of isoflavones and flavones and structuer-activity relationships. Planta Med 2008; 25-32.
45. Muthyala RS, Ju YH, Sheng S, Williams LD, Doerge DR, Katzenellenbogen JA. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R-and Sequols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorganic & Medicinal Chemistry 2004; 12: 1559-1567.
46. Speirs V, Walker RA. New perspectives into the biological and clinical relevance of oestrogen receptors in the human brest. JPathol. 2007; 211: 499-506.
47. Allred CD, Ju YH, Allred KF, Chang J, Halferich G. Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis 2001; 22: 1667-1673.
48. Santell RC, Chang YC, Nair MG, Helferich WG. Dietary genistein exerts estrogenic effects upon uterus, mammary gland and the hypothalamic/pituitary axis in rats. J Nutr 1997; 127: 263-9.
49. Fritz WA, Coward L, Wang J, Lamartiniere CA. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis 1998; 19: 2151-8.
50. Ju YH, Fultz J, Allred KF, Doerge DR, Helferich WG. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer(MCF-7) tumors implanted in ovariectmized athymic mice. Carcinogenesis 2009; 27: 856-63.
51. Liu A, Suzuki N, Laxmi YR Santosh, Okamoto Y, Shibutani A. Anti-breast cancer potential of daidzein in rodents, Life Sci. 2012; 91: 415-9.
52. Wood CE, Stute P, Kaplan JR, Cline JM. Soy effects on the mammary gland of premenopausal female monkeys. Fertil steril; 85: 1179S-86S.
53. Wood CE, Register TC, Cline JM. Soy isoflavonoid effects on endogenons estrogen metabolism in postmenopaual female monkeys. Carcinogenesis2007; 28: 801-8.
54. Hilakivi-Clarke L, Andrade JE, Helferich W. Is soy consumption good or bad for the breast?. J Nutr 2010; 140: 2326S-34S.
55. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 1996; 93: 9776-81.
56. Spink DC, Eugster HP, Lincoln DW, et al. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem Biophys 1992; 293: 342-8.
57. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368: 237-9.
58. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997; 94: 10937-42.
59. Stack DE, Byun J, Gross ML, Rogan EG, Cavalieri EL. Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol 1996; 9: 851-9.
60. Fleck SC, Hildebrand AA, Pfeiffer E, Metzler M. Catechol metabolites of zeranol and 17-estradiol: A comparative in vitro study on the induction of oxidative DNA damage and methylation by catechol-O-methyltransferase. Toxicol Lett 2012; 210(1): 9-14.
61. Chakravarti D, Mailander PC, Li KM, et al. Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 2001; 20: 7945-53.
62. Schutze N, Vollmer G, Tiemann I, Geiger M, Knuppen R. Catecholestrogens are MCF-7 cell estrogen receptor agonists. J Steroid Biochem Mol Biol 1993; 46: 781-9.
63. Van Aswegen CH, Purdy RH, Wittliff JL. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J Steroid Biochem 1989; 32: 485-92.
64. Guillemette C, Belanger A, Lepine J. Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res 2004; 6: 246-54.
65. Aoyama T, Korzekwa K, Nagata K, Gillette J, Gelboin HV, Gonzalez FJ. Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 1990; 126: 3101-6.
66. Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33: 500-8.
67. Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 1997; 18: 207-14.
68. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 1986; 24: 353-6.
69. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000; 60: 235-7.
70. Liehr JG, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci USA 1995; 92: 9220-4.
71. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 1996; 93: 3294-6.
72. Singh S, Chakravarti D, Edney JA, et al. Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma. Oncol Rep 2005; 14: 1091-6.
73. Gestl SA, Green MD, Shearer DA, Frauenhoffer E, Tephly TR, Weisz J. Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers. Am J Pathol 2002; 160: 1467-79.
74. Doostdar H, Burke, MD and Mayer RT. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 2000; 144: 31-8.
75. Chaudhary A. and Willett KL. Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort. Toxicology 2006; 217: 194-205.
76. Chang TK, Chen J. and Yeung EY. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. Toxicol. Appl. Pharmacol 2006; 213: 18-26.
77. Takemura H, Itoh T, Yamamoto K, Sakakibara H, Shimoi K. Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem 2010; 18: 6310-5.
78. Itoh T, Takemura H, Shimoi K, Yamamoto K. A 3D model of CYP1B1 explains the dominant 4-hydroxylation of estradiol. J Chem Inf Model 2010; 50: 1173-8.
79. Takemura H, Uchiyama H, Ohura T, et al. A methoxyflavonoid, chrysoeriol, selectively inhibits the formation of a carcinogenic estrogen metabolite in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 2010; 118: 70-6.
80. Choi DY, Lee JY, Kim MR, Woo ER, Kim YG, Kang KW. Chrysoeriol potently inhibits the induction of nitric oxide synthase by blocking AP-1 activation. J Biomed Sci 2005; 12: 949-59.
81. Khan AU and Gilani AH. Selective bronchodilatory effect of Rooibos tea (Aspalathus linearis) and its flavonoid, chrysoeriol. Eur J Nutr 2006; 45: 463-9.
82. Lin LZ, LUSAnd Harnly JM. Detection and quantification of glycosylated flavonoid malonates in celery, Chinese celery, and celery seed by LC-DAD-ESI/MS. J Agric Food Chem 2007; 55: 1321-6.
83. Snijman PW, Swanevelder S, Joubert E, Green IR, Gelderblom WC. The antimutagenic activity of the major flavonoids of rooibos (Aspalathus linearis): some dose-response effects on mutagen activation-flavonoid interactions. Mutat Res 2007; 631: 111-23.
84. Seo HS, Ju JH, Jang K, Shin I. Induction of apoptotic cell death by phytoestrogens by up-regulating the levels of phospho-p53 and p21 in normal and malignant estrogen receptor alpha-negative breast cells. Nutr Res 2011; 31: 139-46.
85. Lee EJ, Oh SY, Sung MK. Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptormediated pathway in MDA-MB-231 ER-negative breast cancer cells. Food Chem Toxicol 2012; 50: 4136-43.
86. Wang L, Ling Y, Chen Y, et al. Flavonoid baicalein suppresses adhesion, migration and invasion of MDA-MB-231 human breast cancer cells. Cancer Lett 2010; 297: 42-8.
87. Tiong CT, Chen C, Zhang SJ, et al. A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERalpha protein. Carcinogenesis 2012; 33: 1089-97.
88. Bosviel R, Dumollard E, Dechelotte P, Bignon YJ, Bernard-Gallon D. Can soy phytoestrogens decrease DNA methylation in BRCA1 and BRCA2 oncosuppressor genes in breast cancer? OMICS 2012; 16: 235-44.
89. Kim DH, Na HK, Oh TY, Shin CY, Surh YJ. Eupatilin inhibits proliferation of ras-transformed human breast epithelial (MCF-10A-ras) cells. J Environ Pathol Toxicol Oncol 2005; 24(4): 251-9.
90. Seo HS, Choi HS, Choi HS, et al. Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-kappaB signaling in HER2-overexpressing breast cancer cells. Anticancer Res 2011; 31(10): 3301-13.
91. Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol 2012; 4(3): 113-25.
92. Powe DG, Voss MJ, Habashy HO, et al. Alpha-and betaadrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat 2011; 130(2): 457-63.